LinkedInInstagramX
|
Logo
Background object

Meet Synapmed at Booth 94

World Drug Safety Congress

Europe 2025

Booth 94 · 📅 7–8 October 2025 · 📍 RAI, Amsterdam, Netherlands

Join us at the leading global event for pharmacovigilance and drug safety professionals. Discover how Synapmed is advancing Drug Safety, PV Automation, and Regulatory Intelligence with next-generation solutions.

Business professionals meeting

Why Meet Synapmed?

End-to-End Pharmacovigilance & Medical Affairs Support
Patient-Centric, AI-Powered Product suite
Global Regulatory Affairs, HEOR, RWD & RWE Expertise
Audit-Ready Compliance Frameworks
Flexible FSP & Project-Based Models

Whether you are scaling operations or optimizing compliance, our experts will be on-site to share how Synapmed can support your success.

Our Core services

  • Adverse event management
  • Literature surveillance
  • Safety and regulatory writing
  • Extended Access program value chain
  • QPPV support
  • Pharmacovigilance setup
  • Signal management
  • Risk management
  • Quality management framework
  • Learning and Training management
  • Inspection readiness

Meet the team

Gargi Kumari

Gargi Kumari

Chief Executive Officer

Ashish Dwivedi

Ashish Dwivedi

Chief Customer Officer

Dr. Krishnam Rajkumar P

Dr. Krishnam Rajkumar P

Head - Medical Science

Nikita Kalra

Nikita Kalra

Head - Technology

Sai Srinivasa Ravi Teja

Sai Srinivasa Ravi Teja

Head - Quality, Compliance & Training

Reserve Your Meeting Slot

We respect your privacy. Your information is 100% secure.

About Synapmed

Synapmed is a science-led, AI-native full-service CRO transforming drug safety, compliance, and clinical development. With global teams across the USA, Europe, and Asia-Pacific, we deliver end-to-end support, from pre-clinical to post-marketing, spanning pharmacovigilance, clinical trials, regulatory, medical writing, biostatistics, real-world evidence, and medical information. ISO-certified, aligned with global health authorities, and experienced across all therapeutic areas from generics to rare diseases, we bridge innovation and regulation to help pharma accelerate development, reduce risk, and achieve safer patient outcomes worldwide.

Background pattern

Let’s Talk Drug Safety in Amsterdam!